State Of The Union: Ovarian Cancer Patients Living Longer President Obama:
Houston ( AP ) Jan. 21, 2014 /#PRNewswire/ (#GLOBE #NEWSWIRE) –---- ,Today Sam Houston Biotech A Houston based biotech company announced today they are now adding ovarian cancer to their genomic product line. There are many reasons for this additional
product line says Rose Conrad CEO one in particular is that we feel The Afforable Care Act and Genomics can have Women back on their after Ovarian Cancer treatment. Sam Houston has developed a catalog of the genetic aberrations responsible for an aggressive type of ovarian cancer that accounts for 70 percent of all ovarian cancer.
Women with breast cancer diagnosed at age 50 or younger or ovarian cancer at any age meet expert
guidelines for genetic counseling but this service is not specifically covered under the Affordable Care Act
Genomics and Aberrant Genes are the key. Aberrant Genes are genes expressed at the wrong time or inappropriately. By detecting the aberrant genes in a patient, and targeting these genes with therapies that are most effective against the specific mutations.
Sex can feel different after ovarian cancer surgery. Your vagina will be a bit shorter. But it is naturally very stretchy so this shouldn't make too much difference to you and your partner. But remember that
having your womb removed means that you will have stitches at the top of your vagina where your cervix was taken out. So you shouldn't have full sex until these have healed. This takes about 3 or 4 weeks. Is what most doctors tell their patient.
Ovarian cancer is the fifth leading cause of cancer death among women in the U.S., with almost 22,000 new cases and 14,000 deaths estimated for 2010 according to the National Cancer Institute.
High-grade serous ovarian cancer, which begins in the cells on the surface of the ovary, accounts for 90 percent of all ovarian cancers and often remains undetected until it’s quite advanced.
Condrad suggest here we can win, 62% of Ovarian Cancer Patients Under 30 are choosing to freeze entire ovaries or strips of ovarian tissue. A woman diagnosed with early-stage ovarian cancer removal of one ovary has become a real option. This conservative surgery greatly increases the chances of preserving fertility.
There is a 12 percent Chance that the patient will have a recurrence in their remaining ovary and subsequently may die. Most women resumed normal menstruation or had a successful pregnancy.
A network of genes that repairs damaged DNA is defective in about half the tumors. Patients with this defect may benefit from therapies that inhibit this errant function. And they found that the spectrum of mutations in high-grade serous ovarian cancer is distinct from three other ovarian cancer subtypes, which are themselves distinct from each other.
But you may find that you don't feel ready to start being sexually active again that soon. It takes many women much longer than that. You may still have a bit of discomfort, so prefer to wait a bit longer. And you will need to recover emotionally as well as physically. SuperBowl Weekend Kristen Mills In NYC 
You may feel that your womb was an important part of your body and having had it taken away can affect how you feel about yourself sexually. You will no longer be able to become pregnant. And you won't have any more periods. Even if you were past your menopause before the surgery, losing your womb can be a very emotional experience. Many women find this more of a shock than they expected
The molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analyzed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 
of these tumors. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumors (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumors with BRCA1/2 (BRCA1 or BRCA2) andCCNE1 aberrations have on survival.
Chemotherapy (chemo) is the use of drugs to treat cancer. Most often, chemo is a systemic treatment − the drugs are given in a way that allows them to enter the bloodstream and reach all areas of the body. Systemic chemo can be useful for cancers that have metastasized (spread). Most of the time, systemic chemo uses drugs that are injected into a vein (IV) or given by mouth. For some cases of ovarian cancer, chemotherapy may also be injected through a catheter directly into the abdominal cavity. This is called intraperitoneal (IP) chemotherapy. Drugs given this way are also absorbed into the bloodstream, so IP chemotherapy is also a type of systemic chemo.
Among the services included in these regulations are genetic counseling and testing for inherited breast and ovarian cancer risk in women with a family history of cancer. Breast and ovarian cancers have been linked to mutations in the BRCA1 and BRCA2 genes.
The Ovarian Cancer National Alliance, FORCE, Bright Pink and CCARE Lynch Syndrome applaud the government’s attention to women’s health services in general and preventive services in particular. We are happy that genetic counseling and genetic testing will be covered without cost-sharing, as these
are important services for women who may have an increased risk of ovarian and breast cancers. The new regulations are a step in the right direction, but they have only taken us halfway there. We are concerned that the current regulations do not include the following:
• genetic counseling or testing in people with a family history indicative of Lynch Syndrome (which is associated with colon, uterine, and ovarian cancer) or other hereditary cancer syndromes;
• genetic counseling and testing for women who have already been diagnosed with cancer;
• risk-management services such as increased surveillance and prophylactic surgery which has been proven to reduce the risk for developing cancer and the risk of dying in high-risk women; and
• genetic counseling and testing in men. As organizations representing thousands of women and families who have or are at risk of developing hereditary cancer, we will continue to work with appropriate government agencies to ensure coverage of evidence-based services that reduce people’s risk for cancer.
The preventive services covered under the Affordable Care Act are based on recommendations from the United States Preventive Services Task Force and include women with the following risk factors:
• Ashkenazi Jewish women with one first degree relative or two second degree relatives on the same side of the family with breast or ovarian cancer • Non-Ashkenazi Jewish women who have:
• two first-degree relatives who had breast cancer; at least one of these two were diagnosed before age 50;
• three or more first- or second-degree relatives with breast cancer regardless of age at diagnosis;
• a combination of both breast and ovarian cancer among first- and second-degree relatives;
• a first-degree relative with bilateral breast cancer;
• a combination of two or more first- or second- degree relatives with ovarian cancer, regardless of age at diagnosis;
• a first- or second- degree relative with both breast and ovarian cancer at any age; or
• a history of breast cancer in a male relative
These guidelines are based on USPSTF’s Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility recommendations released in 2005. The USPSTF is currently reviewing these guidelines. Revisions in the guidelines could impact preventive services covered by the Affordable Care Act and services available to Medicare beneficiaries. .
People who are concerned that the cancer in their family could be hereditary should consult with a qualified genetics professional prior to proceeding with genetic testing for cancer risk.
No comments:
Post a Comment